Testing new drugs, including LX-101, for relapsed or hard-to-treat Ewing sarcoma
Tests new cancer drugs in teens and young adults with returned Ewing sarcoma.
Plain-language title generated from the registry record
Registry title: RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
Key facts
- Where
- Houston, United StatesSee the site
- Phase
- Phase 2
Where in United States
- MD Anderson Cancer CenterHouston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT07781891
- Record updated
- 24 August 2026
- Original description
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.Read full original descriptionShow less
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
Inclusion: Eligibility Criteria; Age ≥ 10 years (Safety data from ≥3 adult patients must exist before enrolling children); Must have relapsed or chemo-refractory ES, DSRCT, or SRCS. C. Must have received at least 2 prior chemotherapy regimens (typically VIDE or VDC/IE) D. Measurable disease by RECIST (i.e., tumor ≥1 cm in minimal dimension) E. ECOG performance status is 0-2 for adults (Karnofsky/Lansky score ≥60 for children <16 years of age) F. >1 week washout period from any investigational agent and resolution of drug-related AE/SAE to ≤ grade 2.
Exclusion: Uncontrolled or severe cardiac, neurologic, pulmonary, pancreatic, renal, or liver disease; No known personal family history of Long QT syndrome C. History of organ transplant (other than autologous stem cell transplant for cancer), active pneumonitis, myelodysplastic syndrome, or leukemia (acute or chronic) D. Immune or auto-immune-related disorders requiring treatment (treatment for eczema is allowed) E. Investigational agents within 7 days of starting study treatment. F. Major surgery within 28 days before treatment consent (Treatment cannot start with a persistent open wound) G. Leptomeningeal disease or untreated brain metastases. H. Unable to safely hold anticoagulant medication, if taken, for biopsy. I. Psychiatric illness/social situations that would limit compliance with study requirements; Prisoners or participants who are legally institutionalized.